Stock Track | Apellis Pharmaceuticals Soars 140.96% in Pre-Market on $5.6 Billion Biogen Acquisition

Stock Track03-31

Apellis Pharmaceuticals Inc. (APLS) experienced a significant pre-market surge of 140.96%, following news of a major acquisition.

The dramatic price movement is directly attributed to Biogen's announcement that it has agreed to acquire Apellis for approximately $5.6 billion. The deal offers $41.00 per share in cash, which represents a substantial premium of more than double the company's recent closing price.

This acquisition is expected to bolster Biogen's portfolio in immunology and rare diseases, particularly enhancing its nephrology franchise. Apellis brings with it two approved drugs, Syfovre and Empaveli, which generated significant revenue last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136040864?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136040864","market":"sg","top_or_hot":-1,"title":"Stock Track | Apellis Pharmaceuticals Soars 140.96% in Pre-Market on $5.6 Billion Biogen Acquisition","media":"Stock Track","content":"<p>Apellis Pharmaceuticals Inc. (APLS) experienced a significant pre-market surge of 140.96%, following news of a major acquisition.</p><p>The dramatic price movement is directly attributed to Biogen's announcement that it has agreed to acquire Apellis for approximately $5.6 billion. The deal offers $41.00 per share in cash, which represents a substantial premium of more than double the company's recent closing price.</p><p>This acquisition is expected to bolster Biogen's portfolio in immunology and rare diseases, particularly enhancing its nephrology franchise. Apellis brings with it two approved drugs, Syfovre and Empaveli, which generated significant revenue last year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Apellis Pharmaceuticals Soars 140.96% in Pre-Market on $5.6 Billion Biogen Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Apellis Pharmaceuticals Soars 140.96% in Pre-Market on $5.6 Billion Biogen Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-31 19:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apellis Pharmaceuticals Inc. (APLS) experienced a significant pre-market surge of 140.96%, following news of a major acquisition.</p><p>The dramatic price movement is directly attributed to Biogen's announcement that it has agreed to acquire Apellis for approximately $5.6 billion. The deal offers $41.00 per share in cash, which represents a substantial premium of more than double the company's recent closing price.</p><p>This acquisition is expected to bolster Biogen's portfolio in immunology and rare diseases, particularly enhancing its nephrology franchise. Apellis brings with it two approved drugs, Syfovre and Empaveli, which generated significant revenue last year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLS","symbol_name":"Apellis Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1136040864","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136040864","pubTimestamp":1774955807,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Apellis Pharmaceuticals Inc. (APLS) experienced a significant pre-market surge of 140.96%, following news of a major acquisition.The dramatic price movement is directly attributed to Biogen's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLS":"Apellis Pharmaceuticals Inc."},"translate_title":"个股追踪|56亿美元收购百健Apellis制药盘前大涨140.96%","themeId":"b2495f52240e7e9378faffff6c56a404","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":1},"content_text":"Apellis Pharmaceuticals Inc. (APLS) experienced a significant pre-market surge of 140.96%, following news of a major acquisition.The dramatic price movement is directly attributed to Biogen's announcement that it has agreed to acquire Apellis for approximately $5.6 billion. The deal offers $41.00 per share in cash, which represents a substantial premium of more than double the company's recent closing price.This acquisition is expected to bolster Biogen's portfolio in immunology and rare diseases, particularly enhancing its nephrology franchise. Apellis brings with it two approved drugs, Syfovre and Empaveli, which generated significant revenue last year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136040864","isCrawlerRequest":true}